Milnacipran
Top: (1S,2R)-milnacipran (L-milnacipran) Bottom: (1R,2S)-milnacipran (D-milnacipran) | |
| Clinical data | |
|---|---|
| Trade names | Ixel, Joncia, Savella |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a609016 |
| Pregnancy category |
|
| Routes of administration | By mouth (tablets), capsules) |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 85% |
| Protein binding | 13% |
| Metabolism | Hepatic |
| Elimination half-life | 8 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H22N2O |
| Molar mass | 246.354 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (verify) | |
Milnacipran (trade names Ixel, Savella, Dalcipran, Toledomin) is a serotonin–norepinephrine reuptake inhibitor (SNRI) used in the clinical treatment of fibromyalgia, Major depressive disorder, and Neuropathic pain. In the US, it is solely approved for the treatment of Fibromyalgia even though it is also approved for the treatment of Major depressive disorder (but not Fibromyalgia) in others countries (e.g France)